# PanACEA Sutezolid Dose-finding and Combination Evaluation

> **NCT03959566** · PHASE2 · COMPLETED · sponsor: **Michael Hoelscher** · enrollment: 75 (actual)

## Conditions studied

- Pulmonary Tuberculosis
- Other Specified Pulmonary Tuberculosis

## Interventions

- **DRUG:** Sutezolid
- **DRUG:** Bedaquiline, Delamanid, Moxifloxacin
- **DRUG:** Midazolam oral solution

## Key facts

- **NCT ID:** NCT03959566
- **Lead sponsor:** Michael Hoelscher
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-05-06
- **Primary completion:** 2022-09-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 75 (ACTUAL)
- **Last updated:** 2023-05-01

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03959566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03959566, "PanACEA Sutezolid Dose-finding and Combination Evaluation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03959566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*